Novartis Ag Stock Operating Margin
| NVSEF Stock | USD 98.25 6.75 6.43% |
Novartis AG fundamentals help investors to digest information that contributes to Novartis' financial success or failures. It also enables traders to predict the movement of Novartis Pink Sheet. The fundamental analysis module provides a way to measure Novartis' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novartis pink sheet.
Novartis |
Novartis AG Company Operating Margin Analysis
Novartis' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Novartis Operating Margin | 0.25 % |
Most of Novartis' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novartis AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Novartis AG has an Operating Margin of 0.2481%. This is 100.71% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The operating margin for all United States stocks is 104.5% lower than that of the firm.
Novartis Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novartis' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Novartis could also be used in its relative valuation, which is a method of valuing Novartis by comparing valuation metrics of similar companies.Novartis is currently under evaluation in operating margin category among its peers.
Novartis Fundamentals
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0645 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 207.39 B | |||
| Shares Outstanding | 2.12 B | |||
| Shares Owned By Insiders | 3.74 % | |||
| Shares Owned By Institutions | 33.74 % | |||
| Price To Earning | 25.00 X | |||
| Price To Book | 3.22 X | |||
| Price To Sales | 3.82 X | |||
| Revenue | 51.83 B | |||
| Gross Profit | 36.74 B | |||
| EBITDA | 16.39 B | |||
| Net Income | 6.96 B | |||
| Cash And Equivalents | 19.1 B | |||
| Cash Per Share | 8.81 X | |||
| Total Debt | 20.24 B | |||
| Debt To Equity | 0.47 % | |||
| Current Ratio | 1.31 X | |||
| Book Value Per Share | 28.00 X | |||
| Cash Flow From Operations | 14.24 B | |||
| Earnings Per Share | 3.17 X | |||
| Price To Earnings To Growth | 5.67 X | |||
| Number Of Employees | 102 K | |||
| Beta | 0.47 | |||
| Market Capitalization | 183.29 B | |||
| Total Asset | 117.45 B | |||
| Working Capital | 1.28 B | |||
| Current Asset | 25.88 B | |||
| Current Liabilities | 24.6 B | |||
| Z Score | 5.4 | |||
| Annual Yield | 0.04 % | |||
| Five Year Return | 3.29 % | |||
| Net Asset | 117.45 B | |||
| Last Dividend Paid | 3.46 |
About Novartis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novartis AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novartis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novartis AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Novartis Pink Sheet
Novartis financial ratios help investors to determine whether Novartis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novartis with respect to the benefits of owning Novartis security.